ARIA
Library/neuroprotection/Selank

Selank

Not FDA Approved✓ WADA Permitted

Thr-Lys-Pro-Arg-Pro-Gly-Pro / Synthetic Tuftsin analog

neuroprotection○ExperimentalSynthetic immunomodulatory peptide / Anxiolytic

Synthetic heptapeptide developed at Institute of Molecular Genetics (Russia), combining tuftsin fragment (Thr-Lys-Pro-Arg) with a stabilization sequence. FDA-equivalent approved in Russia as nasal drops. Anxiolytic and nootropic. Stabilizes enkephalins, modulates IL-6, influences BDNF and GABA systems.

Confidence
42%
Half-Life ~30 minutes
Cost ~$350/mo
Quick Reference
Routeintranasal / subcutaneous
MechanismSynthetic analog of tuftsin (immunopeptide). Modulates GABAergic system → anxiol...
SequenceThr-Lys-Pro-Arg-Pro-Gly-Pro
Mol. Weight751.86 Da
Reviewed2026-08-08

Mechanism of Action

Synthetic analog of tuftsin (immunopeptide). Modulates GABAergic system → anxiolytic effect. Influences BDNF and NGF expression in hippocampus. Stabilizes enkephalins by inhibiting enkephalin-degrading enzymes. Modulates IL-6 and inflammatory cytokines. Affects monoamine neurotransmission (serotonin, dopamine).

Dosing Protocol

Intranasal: 0.15% solution, 2-3 drops per nostril TID x 10-14 days. SC: 250-500μg daily x 10-14 days.

Key Studies

2009

Selank anxiolytic effects in GAD patients

PMID 19614945clinical_trial
2007

Selank effects on anxiety and psychophysiology

PMID 17258194clinical_trial
2015

Khavinson peptides: geroprotection and Selank review

PMID 26340267review

Adverse Effects

Very well toleratedMild nasal irritation (intranasal)Rare headacheNo serious adverse events reported

Contraindications

  • Hypersensitivity to peptide
  • Pregnancy (insufficient data)
  • Concurrent immunosuppressive therapy (relative)

Storage

Lyophilized: 2-8°C. Nasal solution: room temperature, protected from light. Use within 30 days of opening.

Clinical Applications

  • ["anxiety"
  • "cognitive_support"
  • "stress_resilience"
  • "nootropic"]